Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses the efficacy and safety of acalabrutinib in very old (≥80y) and frail patients with chronic lymphocytic leukemia (CLL), which was evaluated in the Phase II CLL-Frail trial (EudraCT: 2020-002142-17; NCT04883749). Dr Eichhorst highlights that the overall response rate (ORR) in this patient population was high, and, in general, the agent was well-tolerated. This prospective study is the first to focus on this underrepresented patient group, which is expected to expand due to the aging population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть